PubMed 17413599
Referenced in: none
Automatically associated channels: ClC2 , ClC4
Title: Lubiprostone: a chloride channel activator.
Authors: Brian E Lacy, L Campbell Levy
Journal, date & volume: J. Clin. Gastroenterol., 2007 Apr , 41, 345-51
PubMed link: http://www.ncbi.nlm.nih.gov/pubmed/17413599
Abstract
In January 2006 the Food and Drug Administration approved lubiprostone for the treatment of chronic constipation in men and women aged 18 and over. Lubiprostone is categorized as a prostone, a bicyclic fatty acid metabolite of prostaglandin E1. Lubiprostone activates a specific chloride channel (ClC-2) in the gastrointestinal (GI) tract to enhance intestinal fluid secretion, which increases GI transit and improves symptoms of constipation. This article reviews the role of chloride channels in the GI tract, describes the structure, function, and pharmacokinetics of lubiprostone, and discusses clinically important data on this new medication.